Full-Time

Director – Process Engineering

Peptides

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$182k - $346k/yr

+ Short-term Incentive Programs

Waukegan, IL, USA

Hybrid

Hybrid role; on-site days in North Chicago, Illinois. US & Puerto Rico applicants only.

Bachelor's, Master's, MBA

Category
Biology & Biotech (1)
Required Skills
Process Engineering
Risk Management

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • BS, Engineering or equivalent technical degree; Master’s degree in Engineering or MBA preferred
  • 20+ years of experience as a Senior Engineering / Projects / Operations Leader across multiple technologies
  • Proven leadership experience in engineering of mega-capital projects ($500MM – $1B+)
  • Deep knowledge of engineering systems in all disciplines in biopharmaceutical industry
  • Proven inclusive management and leadership capabilities of large cross-functional teams and the ability to effectively interact and communicate with senior leadership and executives from strategic partners and authorities
  • Demonstrated experience managing Engineering contractors and global equipment vendors
  • Results-oriented leadership with outstanding negotiation skills and risk-based decision making is required
  • Ability to mentor and develop next generation of leaders
  • Travel within the US outside the US for reviews/workshops/visits to vendor facilities will be required
Responsibilities
  • Lead a team of Subject matter experts to drive engineering schedules of selected A&E consultants
  • Ensure deliverables are reviewed, approved and issued for design or construction to ensure that the project procurement and construction activities proceed without any interruption
  • Serve as the owner’s senior process engineering leader for major capital projects.
  • Provide leadership to the owner’s process engineering team and coordinate with contractor engineering organizations.
  • Establish process engineering execution strategies and technical standards for the project.
  • Ensure alignment of process designs with manufacturing requirements, regulatory expectations, and corporate engineering standards.
  • Drive cross-functional integration between engineering, operations, quality, and PDS&T teams.
  • Act as the Process Engineering Design Authority, responsible for technical approval and governance of key process engineering deliverables.
  • Provide oversight and approval of critical engineering documents including Process Flow Diagrams (PFDs), Piping and Instrumentation Diagrams (P&IDs), Process schematics and system architecture, Cause and Effect diagrams, control narratives and operations philosophy documentation
  • Lead multidisciplinary design reviews to ensure completeness, operability, and compliance with project standards.
  • Ensure design consistency across engineering disciplines including process, mechanical, utilities, automation, and facility systems.
  • Support corporate capital project governance and stage-gate review processes.
  • Ensure process engineering deliverables are completed to required maturity levels at each project phase
  • Define and oversee process system architecture, system boundaries, and equipment integration.
  • Ensure process systems are effectively integrated with Utility systems, Automation and control systems, Facility infrastructure, Cleanroom and environmental systems
  • Provide technical oversight for development and verification of process fluid lists and line lists.
  • Ensure proper classification of process streams and evaluate material compatibility, corrosion risks, and contamination risks associated with process fluids.
  • Ensure alignment between process fluid characteristics and material selection for piping, valves, and equipment.
  • Provide governance and technical review for process piping design including Pipe sizing and hydraulic calculations, Pressure drop and flow rate analysis, Line classification and specifications
  • Ensure piping designs support process reliability, cleanability, maintainability, and sterility where applicable.
  • Ensure process systems meet corporate and regulatory process safety management (PSM) requirements including
  • Provide oversight for process safety analyses including Relief valve sizing calculations, Overpressure protection analysis, Process hazard analysis (PHA), HAZOP facilitation and resolution
  • Review safety-critical calculations and engineering analyses.
  • Lead development and approval of operations philosophy documentation defining system operation, control strategies, and operational boundaries.
  • Ensure process systems support safe startup, shutdown, maintenance, and cleaning activities.
  • Integrate operational considerations into design including human factors, accessibility, and maintainability.
  • Collaborate with operations and MSAT teams to ensure long-term operability of process systems.
  • Support systemization and turnover to CQV teams by providing technical support during system startup and operational readiness activities.
  • Lead resolution of process engineering issues identified during commissioning and qualification.
  • Monitor contractor performance, deliverables quality, and resource utilization.
  • Ensure efficient coordination between contractor teams and internal engineering resources.
  • Oversee engineering budgets and resource plans across the project lifecycle.
  • Ensure efficient utilization of both internal and contractor engineering resources.
  • Support development of capital cost estimates and engineering schedules.
  • Identify and mitigate risks that could impact project cost or timeline.
  • Contribute to and lead a high-performing project organization including program managers, engineering leads, construction managers, CQV leads, and project controls professionals.
  • Foster a culture of safety, accountability, collaboration, and operational excellence.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.